- Home
- MSSA vs ALXO Comparison
MSSA vs ALXO Comparison
Compare MSSA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSSA
- ALXO
- Stock Information
- Founded
- MSSA 2021
- ALXO 2015
- Country
- MSSA United States
- ALXO United States
- Employees
- MSSA N/A
- ALXO N/A
- Industry
- MSSA
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MSSA
- ALXO Health Care
- Exchange
- MSSA NYSE
- ALXO Nasdaq
- Market Cap
- MSSA 74.6M
- ALXO 76.5M
- IPO Year
- MSSA 2022
- ALXO 2020
- Fundamental
- Price
- MSSA $11.70
- ALXO $2.00
- Analyst Decision
- MSSA
- ALXO Strong Buy
- Analyst Count
- MSSA 0
- ALXO 5
- Target Price
- MSSA N/A
- ALXO $13.25
- AVG Volume (30 Days)
- MSSA 1.4K
- ALXO 1.1M
- Earning Date
- MSSA 01-01-0001
- ALXO 11-07-2024
- Dividend Yield
- MSSA N/A
- ALXO N/A
- EPS Growth
- MSSA N/A
- ALXO N/A
- EPS
- MSSA 0.19
- ALXO N/A
- Revenue
- MSSA N/A
- ALXO N/A
- Revenue This Year
- MSSA N/A
- ALXO N/A
- Revenue Next Year
- MSSA N/A
- ALXO N/A
- P/E Ratio
- MSSA $61.84
- ALXO N/A
- Revenue Growth
- MSSA N/A
- ALXO N/A
- 52 Week Low
- MSSA $10.94
- ALXO $1.19
- 52 Week High
- MSSA $14.48
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- MSSA 48.07
- ALXO 60.32
- Support Level
- MSSA $11.70
- ALXO $1.40
- Resistance Level
- MSSA $12.00
- ALXO $1.88
- Average True Range (ATR)
- MSSA 0.47
- ALXO 0.19
- MACD
- MSSA -0.02
- ALXO 0.02
- Stochastic Oscillator
- MSSA 2.14
- ALXO 81.15
About MSSA METAL SKY STAR ACQUISITION CORP
Metal Sky Star Acquisition Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.